Learning from recombinant GH treatment in obesity
Silvia Vandeva1, Martine Rixhon2, Maria A. Tichomirowa1, Maria C. Burlacu1, Sabina Zacharieva3, Adrian F. Daly1, and Albert Beckers1
1Dept. of Endocrinology, and 2Dept. of GeneralMedicine, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium, 3Dept. of Endocrinology, University Hospital of Endocrinology and Gerontology "Ivan Pentchev",Medical University, Sofia, Bulgaria

Obese and untreated growth hormone deficiency (GHD) patients have a number of similar clinical and biological abnormalities. Treatment with recombinant human growth hormone (rhGH) in GHD patients has proven effective in beneficially modulating body composition and certain cardiovascular risk factors, thus leading to the hypothesis that administration of rhGH in obese patients could show similar beneficial results. Hyperinsulinism and increased free fatty acid levels are the main factors causing reduced GH release in the setting of obesity. We reviewed the outcomes of 25 adult and paediatric clinical studies carried out in 1987-2009 that examined the effects of rhGH administration in the obese state. Body composition showed mainly a reduction in visceral abdominal fat, whereas total bodyweight increased or remained unchanged. Effects of rhGH on lipid and carbohydrate metabolic profiles in obese patients were heterogeneous. The increasing burden of obesity on one hand, the absence of definitive medical treatment on the other, give rise to grounds for considering rhGH as a possible therapeutic option if not in the general obese population, at least in patients with higher risk of cardiovascular morbidity and mortality.

[« Torna indietro] [Full text non abbonati] [Full text abbonati] [Acquista PDF]